Medpace Holdings, Inc. $MEDP Shares Sold by Findlay Park Partners LLP

Findlay Park Partners LLP lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 302,300 shares of the company’s stock after selling 5,300 shares during the quarter. Medpace makes up about 1.6% of Findlay Park Partners LLP’s holdings, making the stock its 27th biggest holding. Findlay Park Partners LLP owned about 1.07% of Medpace worth $155,431,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MEDP. Handelsbanken Fonder AB grew its stake in shares of Medpace by 16.7% during the third quarter. Handelsbanken Fonder AB now owns 7,700 shares of the company’s stock worth $3,959,000 after purchasing an additional 1,100 shares in the last quarter. Diversify Wealth Management LLC lifted its holdings in Medpace by 4.7% during the 3rd quarter. Diversify Wealth Management LLC now owns 3,154 shares of the company’s stock worth $1,622,000 after buying an additional 143 shares during the last quarter. Citizens Business Bank acquired a new position in shares of Medpace during the 3rd quarter worth about $920,000. Intech Investment Management LLC increased its holdings in shares of Medpace by 31.9% in the 3rd quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock valued at $9,458,000 after acquiring an additional 4,448 shares during the last quarter. Finally, Empirical Asset Management LLC increased its holdings in shares of Medpace by 9.8% in the 3rd quarter. Empirical Asset Management LLC now owns 2,189 shares of the company’s stock valued at $1,125,000 after acquiring an additional 196 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $451.76 on Friday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The stock has a market cap of $12.82 billion, a P/E ratio of 29.53, a P/E/G ratio of 2.14 and a beta of 1.42. The firm has a fifty day moving average price of $544.42 and a 200 day moving average price of $538.27.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on MEDP shares. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and lowered their price target for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Truist Financial dropped their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Leerink Partners reduced their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Finally, Barclays dropped their price objective on Medpace from $525.00 to $500.00 and set an “underweight” rating on the stock in a report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $483.45.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 23,178 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $593.25, for a total value of $13,750,348.50. Following the transaction, the chief executive officer owned 652,550 shares of the company’s stock, valued at approximately $387,125,287.50. The trade was a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.